CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 92 enrolled
Drug / intervention
Real-Time PCRgenetic
Likely dose
Real-Time PCR 2 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05093023
NCT05093023N/ACompleted

ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer

Ain Shams University·observational·Posted Oct 26, 2021·Updated Oct 26, 2021

In Brief

An observational study evaluating Real-Time PCR for Paclitaxel Adverse Reaction and 2 related conditions. Completed, enrolled 92 participants across 1 site.

Detailed Summary

The study aim is to determine the allele frequencies of 1236 G\>A and 3435 G\>A in ABCB1 and study their association with the incidence and severity of paclitaxel-induced peripheral neuropathy while adjusting for other baseline covariates in Egyptian patients. Additionally, the study aimed at fitting and validating logistic regression models with the aforementioned SNPs evaluated in additive, dominant, overdominant, and recessive genetic models and performing diagnostics for the best model in terms of internal validity.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 26, 2021
Enrollment StartMar 1, 2018
Primary CompletionJan 1, 2020
Study CompletionJan 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.7 years ago

Interventions

Real-Time PCRgenetic

Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G\>A and 3435 G\>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.